STI Knowledge and HPV Vaccine Acceptance in Bamako, Mali in 2012

March 1, 2023 updated by: Global Alliance to Immunize Against AIDS Vaccine Foundation

Knowledge, Attitudes, Practices and Willingness to Vaccinate in Preparation for the Introduction of HPV Vaccines in Bamako, Mali

Although screening for pre-cancerous cervical lesions and human papilloma virus (HPV) vaccination are accepted and effective means to prevent cervical cancer, women in Mali have limited access to these interventions. In addition, cervical cancer prevention by HPV vaccination has been controversial in some settings. To reduce cervical cancer prevalence and increase HPV vaccine uptake, it is important to understand the level of knowledge about cervical cancer screening and practices related to vaccination in at-risk populations. In this study, the level of knowledge about HPV and cervical cancer and attitudes towards vaccination were assessed among 301 participants (male and female, adults and adolescents) in a house-to-house survey in two urban neighborhoods in Bamako, Mali. The survey was combined with a brief educational session on HPV. Prior to the education session, overall knowledge of HPV infection and cervical cancer was very low: only 8% knew that HPV is a sexually transmitted infection (STI). Less than 20% of women had ever consulted a gynecologist and less than 3% had ever had cervical cancer screening. After hearing a description of HPV vaccine, more than 80% would accept HPV vaccination; fathers and husbands were identified as primary decisions makers and local clinics or the home as preferred sites for vaccination. This study provides information on STI knowledge and vaccine acceptance in Bamako, Mali in 2012, prior to the introduction of HPV vaccination.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

301

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants were recruited between May and June 2011 in Mèkin-Sikoro and Djikoroni, two peri-urban communities of Bamako that have been site for previous population surveys. Adolescents were eligible if aged 12-17 years and living in the household, and if a guardian was available to provide consent. Adults (male and female) were eligible if aged >18 years and living in the household. A total of 301 participants participated (150 living in households in Djikoroni, 151 living in Me´kin-Sikoro)

Description

Inclusion Criteria:

  • 12-17 years of age, with guardian consent
  • 18 years or older
  • Male or Female
  • Living in Mèkin-Sikoro and Djikoroni

Exclusion Criteria:

  • 12-17 years of age, without guardian consent
  • <12 years of age
  • Living outside Mèkin-Sikoro and Djikoroni

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Bamako Participants
301 male and female participants. Teenagers and adults. Living in two urban regions of Bamako.
Behavioral: HPV Vaccine Acceptance Survey

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participants' acceptance of the vaccine
Time Frame: immediately after the intervention
Number of participants willing to be vaccinated against HPV and their vaccination preferences after educational sessions
immediately after the intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Knowledge of STIs, HPV, and Cervical Cancer
Time Frame: immediately after the intervention
Knowledge Question asked before and after educational session
immediately after the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Global Alliance to Immunize Against AIDS Vaccine Foundation

Collaborators

Merck Sharp & Dohme LLC

Investigators

  • Principal Investigator: Anne De Groot, MD, GAIA Vaccine Foundation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2011

Primary Completion (Actual)

May 1, 2011

Study Completion (Actual)

June 1, 2011

Study Registration Dates

First Submitted

October 26, 2022

First Submitted That Met QC Criteria

March 1, 2023

First Posted (Actual)

March 14, 2023

Study Record Updates

Last Update Posted (Actual)

March 14, 2023

Last Update Submitted That Met QC Criteria

March 1, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • HPV Vaccine Survey

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HPV-Related Cervical Carcinoma

Clinical Trials on HPV Vaccine Acceptance Survey

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe